Skip to main content

Ciulla Thomas's Form 4 filing

Clearside Biomedical, Inc. (CLSD) · filed Jan 20, 2022

Accession no.
0001209191-22-004193
Filed
Jan 20, 2022
Trade date
Jan 18-19, 2022
Filing delay
2 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $19.3K. It was filed 2 days after the trade.

This filing was later replaced by the amendment 0001209191-22-005440 (Jan 28, 2022). Trade tables on this site use the amended version.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Ciulla ThomasCIK 0001815426Officer (Chief Medical Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jan 18, 2022Common StockAGrant or awardAcquired+43,750$0.00$0299,310Direct
Jan 19, 2022Common StockSSaleDisposed−9,050$2.13−$19,276.5295,260Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Jan 18, 2022Common StockAGrant or awardAcquired+131,250$0.00$0131,250Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

No transaction price on this filing refers to a footnote.

Read the full filing on SEC EDGAR (opens in a new tab)